Samrat S. Khichi
Known title: EVP, CPO and General CounselCIK: 0001612227
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
Transaction History
| CVS | ▼ Sell | Tax Withholding | 3,541 | $257K | 4/1/2026 | View on chart |
| CVS | ▲ Buy | Grant | 12,531 | $900K | 3/31/2026 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 7,886 | $628K | 2/28/2026 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 1,548 | $105K | 4/1/2025 | View on chart |
| CVS | ▲ Buy | Grant | 16,181 | $1.1M | 4/1/2025 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 5,604 | $368K | 2/28/2025 | View on chart |
| CVS | ▲ Buy | Grant | 12,569 | $0 | 4/1/2024 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 6,210 | $467K | 2/28/2024 | View on chart |
| CVS | ▲ Buy | Grant | 47,881 | $4.0M | 2/28/2023 | View on chart |
| BDX | ▼ Sell | Gift | 19 | $0 | 12/21/2022 | View on chart |
| BDX | ▼ Sell | Gift | 40 | $0 | 12/13/2022 | View on chart |
| BDX | ▲ Buy | Grant | 3,334 | $0 | 11/26/2022 | View on chart |
| BDX | ▲ Buy | Grant | 1,956 | $0 | 11/26/2022 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 1,908 | $0 | 11/26/2022 | View on chart |
| BDX | ▲ Buy | Option Exercise | 14,326 | $1.3M | 8/9/2022 | View on chart |
| BDX | ▼ Sell | Other | 5,141 | $1.3M | 8/9/2022 | View on chart |
| BDX | ▼ Sell | Open Market | 9,185 | $2.4M | 8/9/2022 | View on chart |
| BDX | ▲ Buy | Option Exercise | 12,489 | $1.4M | 8/9/2022 | View on chart |
| BDX | ▼ Sell | Other | 5,194 | $1.4M | 8/9/2022 | View on chart |
| BDX | ▼ Sell | Open Market | 7,295 | $1.9M | 8/8/2022 | View on chart |
| BDX | ▼ Sell | Gift | 375 | $0 | 2/8/2022 | View on chart |
| BDX | ▲ Buy | Grant | 990 | $0 | 11/26/2021 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 681 | $0 | 11/26/2021 | View on chart |
| BDX | ▲ Buy | Grant | 1,914 | $0 | 11/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status
CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.
CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status. CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.